Global Point of Care (PoC) Imaging Devices Market to Reach $19.84 Billion by 2030

According to a new market intelligence report by BIS Research titled “Global Point of Care imaging devices Market – Analysis & Forecast 2020-2030”, The global point of care (PoC) imaging devices market was valued at $8.66 billion in 2019 and is expected to reach $19.84 billion by the end of 2030, clocking a CAGR of 8.70%, during the forecast period.

BIS Research Report - https://bisresearch.com/industry-report/point-of-care-imaging-devices-market.html

The diagnostic imaging technology ecosystem is facing significant changes in its market dynamics as new methodologies, technologies, and practices are currently being introduced in the market. The ecosystems are going through a period of amendments, driven by increasing demand for emerging technologies and its adoption in the healthcare sector. Several other factors ranging rising aging population to secure economic development in the emerging nations too are driving the growth of the PoC imaging devices market.

Request for a Sample: https://bisresearch.com/requestsample?id=952&type=download

Some of the key drivers for the growth of the point of care (PoC) imaging devices market include growing need for more patient convenience, increased healthcare spending by countries to ramp up their healthcare infrastructure, and higher preference due to economic consideration.

PoC imaging devices are aimed at ensuring minimum inconvenience for patients. Thus, point of care imaging devices can be used at a patient’s bedside. The places include hospitals, ambulatory surgical centers, and also their homes. The use of handheld devices allows the scan to be performed at the patients’ homes, reducing or eliminating the need for hospital visits and is particularly useful for elderly patients. Furthermore, the use of handheld PoC enabled devices is now more relevant due to the ongoing COVID-19 pandemic.

The PoC imaging devices market comprises some of the leading players in the medical imaging ecosystem. These include Siemens Healthineers, Koninklijke Philips N.V., General Electric Company, Shimadzu Corporation, Fujifilm Holdings Corporation, Samsung Electronics Co., Ltd., Canon Inc., and Digirad Corporation, among others. Additionally, there has been an increasing number of start-ups in the market which are gaining prominence or are expected to launch their product soon, including Butterfly Network, Inc., Hyperfine Research, and Perimeter Medical Imaging, among others.

The answers to the following key questions can be derived from this report:

· What are the key regulations governing the Point-of-Care (PoC) Imaging devices market?

· What are the key technological developments on which the current industry leaders are spending a major share of their R&D investment?

· How is the role of PoC imaging devices expected to evolve in the future?

· What level of impact will the COVID-19 crisis have on the market in terms of change in demand and the functioning of the supply chain?

· Which leading players are holding a major share of the PoC imaging devices market?

· What are the current business models and key strategies adopted by leading players, and how likely are those models to persist in future market scenarios?

Pharmacogenomics Services Market Dynamics, Competitive Landscape & Forecast to 2031

BIS healthcare experts have found the pharmacogenomics services industry to be one of the most rapidly evolving and dynamic markets. The global pharmacogenomics services market is projected to reach $9,346.8 million by 2031 from $5,060.0 million in 2020, at a CAGR of 5.71% during the forecast period 2021-2031. The market is driven by certain factors, including increasing prevalence of infectious diseases and various types of cancer, increasing adoption of personalized medicine shifting the paradigm from reaction to prevention, increasing rate of adverse drug reaction, and surge in usage of pharmacogenomics for drug discovery and development. Currently, the pharmacogenomics services industry is witnessing an upsurge due to the increasing prevalence of infectious diseases and various types of cancer, increase in adoption of personalized medicine shifting the paradigm from reaction to prevention, increasing rate of adverse drug reaction, and surge in usage of pharmacogen...

Global Liquid Biopsy Market is Projected to Reach $12,933 Million by 2030

According to a new market intelligence report by BIS Research titled ‘Global Liquid Biopsy Market – Analysis and Forecast, 2020-2030’, The liquid biopsy market is projected to reach $12,933 million by 2030 from $2588.6 million in 2019, at a CAGR of 15.87% during the forecast period 2020-2030 BIS Research Report: https://bisresearch.com/industry-report/global-liquid-biopsy-market.html This growth has been primarily attributed to the rising number of cancer cases coupled up with the growing awareness pertaining to non-invasive detection approaches, the increasing adoption of inorganic growth strategies by key players in the market, and the increasing research funding from the leading organizations such as the U.S. National Institute of Health, globally. The market is expected to grow at a significant growth rate due to opportunities such as the introduction of informatics and technological innovations for a large customer base and increasing adoption of cancer and other disea...

Microbiome Therapeutics Market Growth, Segmentation, Opportunity and Forecast to 2032

Global microbiome therapeutics market is expected to grow further in the coming years due to the continuous increase in awareness and need for better and safer treatment alternatives and the dominance of gastrointestinal (GI) and infectious diseases segment can be attributed to the existing dominance of microbiome therapeutics available for a variety of indications ranging from diarrhea and gut dysbiosis to skin disorders, cancer indications among others. The global microbiome therapeutics market which accounted for $306.3 million in 2021 is expected to reach $3,204 million by 2032, reporting a CAGR of 24.95% during the forecast period 2022-2032. The existing microbiome therapeutics market is favored by multiple factors, including the rising geriatric populations coupled with the increasing adoption of inorganic growth strategies by key players in the market. Impact of COVID-19 There were numerous consequences due to the COVID-19 pandemic, especially...

Market Research Reports

Search This Blog